Financial Performance - The corrected operating revenue for 2023 is CNY 165,071,927.79, a decrease of 23.61% compared to the previous year's CNY 216,082,516.98[4] - The net profit attributable to shareholders decreased by 64.68% to CNY 14,485,196.39 from CNY 41,013,230.25 in the previous year[4] - The net profit after deducting non-recurring gains and losses is CNY 5,167,932.81, down 85.94% from CNY 36,749,294.34 year-on-year[4] - Basic earnings per share decreased by 73.08% to CNY 0.21 from CNY 0.78 in the previous year[4] Asset Management - The total assets at the end of the reporting period increased by 5.55% to CNY 458,091,452.82 from CNY 433,992,572.72 at the beginning of the period[5] - The weighted average return on net assets (after deducting non-recurring items) is 1.83%, a decrease of 1.12 percentage points compared to the previous figure[6] - The company adjusted accounts receivable and contract assets, leading to an increase in credit and asset impairment losses[6] Corporate Communication - The company has issued a risk warning in its previous earnings announcement on February 26, 2024[7] - The board of directors has apologized for the inconvenience caused by the earnings report correction[9] - The financial data in the earnings report is subject to the final figures disclosed in the 2023 annual report[8]
春光药装(838810) - 2023 Q4 - 年度业绩(更正)